Tidal Investments LLC Has $3.64 Million Stake in Haleon PLC Sponsored ADR $HLN

Tidal Investments LLC cut its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 66.6% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 390,259 shares of the company’s stock after selling 779,210 shares during the quarter. Tidal Investments LLC’s holdings in Haleon were worth $3,641,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Parkside Financial Bank & Trust lifted its holdings in Haleon by 20.4% in the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after buying an additional 1,055 shares during the period. Quotient Wealth Partners LLC lifted its stake in Haleon by 7.9% in the first quarter. Quotient Wealth Partners LLC now owns 16,407 shares of the company’s stock valued at $164,000 after buying an additional 1,195 shares during the period. Clearstead Advisors LLC lifted its stake in Haleon by 5.8% in the fourth quarter. Clearstead Advisors LLC now owns 25,847 shares of the company’s stock valued at $261,000 after buying an additional 1,406 shares during the period. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Haleon by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 63,726 shares of the company’s stock worth $644,000 after buying an additional 1,431 shares in the last quarter. Finally, Personal CFO Solutions LLC lifted its position in shares of Haleon by 11.5% during the 1st quarter. Personal CFO Solutions LLC now owns 15,673 shares of the company’s stock valued at $157,000 after acquiring an additional 1,620 shares during the period. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on HLN shares. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a report on Monday, August 24th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Zacks Research upgraded Haleon from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

Haleon Price Performance

Haleon stock opened at $9.39 on Tuesday. The stock has a market cap of $41.28 billion, a P/E ratio of 24.07, a P/E/G ratio of 2.05 and a beta of 0.12. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The company’s 50 day moving average price is $9.85 and its two-hundred day moving average price is $9.67. Haleon PLC Sponsored ADR has a 52 week low of $8.65 and a 52 week high of $11.28.

Haleon Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, September 17th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.0642 per share. This represents a yield of 132.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon’s dividend payout ratio is 30.77%.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK’s consumer healthcare business and became an independent company in 2022.